Collagen-based wound dressings for the treatment of diabetes-related foot ulcers: A systematic review

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 17-29

  Holmes, Crystal ^a   Wrobel, James S ^a   Maceachern, Mark P ^b   Boles, Blaise R ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bio films; Dressings; Matrix; Scaffold; Wound healing

Indexed keywords

ALGINIC ACID; COLLAGEN DERIVATIVE; GAM 501; PLATELET DERIVED GROWTH FACTOR B; PROTEINASE INHIBITOR; SILVER; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

AMNION; ARTICLE; BONE MARROW; COLLAGEN WOUND DRESSING; CONTROLLED STUDY; DEBRIDEMENT; DIABETIC FOOT; EPITHELIZATION; GEL; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SILVER COLLAGEN WOUND DRESSING; SYSTEMATIC REVIEW; TISSUE ENGINEERING; TREATMENT DURATION; WOUND DRESSING; WOUND HEALING; XENOGRAFT COLLAGEN WOUND DRESSING;

EID: 84872960657     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s36024     Document Type: Article

References (75)

1. Landsman A, Taft D, Riemer K. The role of collagen bioscaffolds, foamed collagen, and living skin equivalents in wound healing. Clin Podiatr. Med Surg. 2009;26(4):525-533.
2. Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34(12):1544-1556.
3. Mustoe TA, O'Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg. 2006;117(Suppl 7):S35-S41.
4. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007;44(4):562-565.
5. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50(1):18-25.
6. Patti J, Boles JO, Höök M. Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus. Biochemistry. 1993;32(42):11428-11435.
7. Rich RL, Kreikemeyer B, Owens RT, et al. Ace is a collagen-binding MSCRAMM from Enterococcus faecalis. J Biol Chem. 1999;274(38):26939-26945.
8. Lannergård, J, Frykberg L, Guss B. CNE, a collagen-binding protein of Streptococcus equi. FEMS Microbiol Lett. 2003;222(1):69-74.
9. Patti J, Allen BL, McGavin MJ, Höök M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 1994;48:585-617.
10. Hienz S, Schennings T, Heimdahl A, Flock JI. Collagen binding of Staphylococcus aureus is a virulence factor in experimental endocarditis. J Infect Dis. 1996;174(1):83-88.
11. Mamo W, Fröman G, Muller HP. Protection induced in mice vaccinated with recombinant collagen-binding protein (CnBP) and alpha-toxoid against intramammary infection with Staphylococcus aureus. Microbiol Immunol. 2000;44(5):381-384.
12. Rhem MN, Lech EM, Patti JM, et al. The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitis. Infect Immun. 2000;68(6):3776-3779.
13. Elasri MO, Thoma JR, Skinner RA, et al. Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone. 2002;30(1):275-280.
14. Gottrup F. Controversies in performing a randomized control trial and a systemic review. Wound Repair Regen. 2012;20(4):447-448.
15. Hinchliffe RJ, Valk GD, Apelqvist J, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2008;24 Suppl 1:S119-S144.
16. Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28 Suppl 1:S119-S141.
17. Gottrup F, Apelqvist J, Price P; for European Wound Management Association Patient Outcome Group. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care. 2010;19(6):237-268.
18. Boulton AJ, Armstrong DG. Trials in neuropathic diabetic foot ulceration: time for a paradigm shift? Diabetes Care. 2003;26(9):2689-2690.
19. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22(5):692-695.
20. Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. 2000;135(6):627-634.
21. Edmonds M; for European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8(1):11-18.
22. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002;28(8):698-703.
23. Veves A, Falanga V, Armstrong DG, Sabolinski ML; for Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295.
24. Brem H, Young J, Tomic-Canic M, Isaacs C, Erlich HP. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg Technol Int. 2003;11:23-31.
25. Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. 2010;100(1):73-77.
26. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs. 1997;21(11):1203-1210.
27. Gentzkow GD, Iwasaki, SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19(4):350-354.
28. Kashefsky HE. Outcomes of total contact casting combined with dermagraft in the treatment of 15 consecutive diabetic foot ulcers. Wound Repair Regen. 2011;19(2):A31.
29. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006;3(3):181-187.
30. Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005;2(2):161-165.
31. Landsman A, Roukis TS, DeFonzo DJ, Agnew P, Petranto RD, Surprenant M. Living cells or collagen matrix: Which is more beneficial in the treatment of diabetic foot ulcers? Wounds. 2008;20(5):111-116.
32. Iorio ML, Goldstein J, Adams M, Steinberg J, Attinger C. Functional limb salvage in the diabetic patient: the use of a collagen bilayer matrix and risk factors for amputation. Plast Reconstr Surg. 2011;127(1):260-267.
33. Fleischli JG, Laughlin TJ, Fleischli JW. Equine pericardium collagen wound dressing in the treatment of the neuropathic diabetic foot wound: a pilot study. J Am Podiatr Med Assoc. 2009;99(4):301-305.
34. Clerici G, Caminiti M, Curci V, Quarantiello A, Faglia E. The use of a dermal substitute to preserve maximal foot length in diabetic foot wounds with tendon and bone exposure following urgent surgical debridement for acute infection. Int Wound J. 2010;7(3):176-183.
35. Liao HC, Huang HS, Huang MJ, Chen CC. Preliminary experience with growth factor and porcine graft-young collagenous wettable membrane in the treatment of chronic diabetic ulcer. Changgeng Yi Xue Za Zhi. 1991;14(2):89-94.
36. Parsons D, Bowler PG, Myles V, Jones S. Silver antimicrobial dressings in wound management: a comparison of antibacterial, physical, and chemical characteristic. Wounds. 2005;17(8):222-232.
37. Chaw KC, Manimaran M, Tay FE. Role of silver ions in destabilization of intermolecular adhesion forces measured by atomic force microscopy in Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother. 2005;49(12):4853-4859.
38. Kostenko V, Lyczak J, Turner K, Martinuzzi RJ. Impact of silver-containing wound dressings on bacterial biofilm viability and susceptibility to antibiotics during prolonged treatment. Antimicrob Agents Chemotherapy. 2010;54(12):5120-5131.
39. Thorn RM, Austin AJ, Greenman J, Wilkins JP, Davies PJ. In vitro comparison of antimicrobial activity of iodine and silver dressings against biofilms. J Wound Care. 2009;18(8):343-346.
40. Percival SL, Bowler P, Woods EJ. Assessing the effect of an antimicrobial wound dressing on biofilms. Wound Repair Regen. 2008;16(1):52-57.
41. Gottrup F, et al. Collagen/ORC/silver treatment of diabetic foot ulcers: A randomised controlled trial. Wound Repair Regen. 2011;19(2):A24.
42. Ulrich D, Smeets R, Unglaub F, Wöltje M, Pallua N. Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers. J Wound Ostomy Continence Nurs. 2011;38(5):522-528.
43. Donaghue VM, Chrzan JS, Rosenblum BI, Giurini JM, Habershaw GM, Veves A. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care. 1998;11(3): 114-119.
44. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications. 2006;20(5):329-335.
45. Motzkau M, Tautenhahn J, Lehnert H, Lobmann R. Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing. Exp Clin Endocrinol Diabetes. 2011;119(5):286-290.
46. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137(7):822-827.
47. Marston WA, Usala A, Hills RS, Mendes R, Minsley MA. Initial report of the use of an injectable porcine collagen-derived matrix to stimulate healing of diabetic foot wounds in humans. Wound Repair Regen. 2005;13(3):243-247.
48. Blume P, Driver VR, Tallis AJ, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. Wound Repair Regen. 2011;19(3):302-308.
49. Ravari H, Hamidi-Almadari D, Salimifar M, Bonakdaran S, Parizadeh MR, Koliakos G. Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue and collagen matrix. Cytotherapy. 2011;13(6):705-711.
50. Snyder RJ, Richter D, Hill ME. A retrospective study of sequential therapy with advanced wound care products versus saline gauze dressings: comparing healing and cost. Ostomy Wound Manage. 2010;56 Suppl 11A:S9-S15.
51. Lázaro-Martinez JL, Aragón-Sánchez FJ, Garcia-Morales E, Beneit-Montesinos JV, González-Jurado M. A retrospective analysis of the cost-effectiveness of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers. Ostomy Wound Manage. 2010;56 Suppl 11A:S4-S8.
52. Wu SC, Jensen JL, Weber AK, Robinson DE, Armstrong DG. Use of pressure offloading devices in diabetic foot ulcers: do we practice what we preach? Diabetes Care. 2008;31(11):2118-2119.
53. Fife C. Wound care in the 21st century. In: Sancha A, editor. US Surgery. 2007. Touch Briefing; 2007: 63-64. Available from: http://www.touchbriefings.com/pdf/2742/fife.pdf. Accessed August 6, 2012.
54. Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003;26(9):2595-2597.
55. Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One. 2008;3(10):e3326.
56. Gontcharova V, Youn E, Sun Y, Wolcott RD, Dowd SE. A comparison of bacterial composition in diabetic ulcers and contralateral intact skin. Open Microbiol J. 2010;4:8-19.
57. Viswanathan V, Jasmine JJ, Snehalatha C, Ramachandran A. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India. 2002;50:1013-1016.
58. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med.1986;146(10):1935-1940.
59. Tarnuzzer R, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen. 1996;4(3):321-325.
60. Robson MC, Stenberg BD, Heggers JP. Would healing alterations caused by infection. Clin Plast Surg. 1990;17(3):17:485-492.
61. Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloprotease-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002;10(1):26-37.
62. Bucknall T. The effect of local infection upon wound healing: an experimental study. Br J Surg. 1980;67(12):851-855.
63. McGuckin M, Goldman R, Bolton L, Salcido R. The clinical relevance of microbiology in acute and chronic wounds. Adv Skin Wound Care. 2003;16(1):12-25.
64. Dowd SE, Wolcott RD, Kennedy J, Jones C, Cox SB. Molecular diagnostics and personalised medicine in wound care: assessment of outcomes. J Wound Care. 2011;20(5):232, 234-239.
65. Wolcott RD, Cox SB, Dowd SE. Healing and healing rates of chronic wounds in the age of molecular pathogen diagnostics. J Wound Care. 2010;19(7):272-278, 280-281.
66. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time- dependent therapeutic window. J Wound Care. 2010;19(8):320-328.
67. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008;16(1):37-44.
68. Davis SC, Ricotti C, Cazzaniga A, Welsh E, Eaglstein WH, Mertz PM. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. Wound Repair Regen. 2008;16(1):23-29.
69. Potempa J, Pike RN. Corruption of innate immunity by bacterial proteases. J Innate Immun. 2009;1(2):70-87.
70. Massimi I, Park E, Rice K, Muller-Esterl W, Sauder D, McGavin MJ. Identification of a novel maturation mechanism and restricted substrate specificity for the SspB cysteine protease of Staphylococcus aureus. J Biol Chem. 2002;277(44):41770-41777.
71. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog. 2008;4(4):e1000053.
72. Boles BR, Thoendel M, Roth AJ, Horswill AR. Identification of genes involved in polysaccharide-independent Staphylococcus aureus biofilm formation. PLoS One. 2010;5(4):e10146.
73. Lauderdale KJ, Boles BR, Cheung AL, Horswill AR. Interconnections between Sigma B, agr, and proteolytic activity in Staphylococcus aureus biofilm maturation. Infect. Immun. 2009;77(4):1623-1635.
74. Letendre S, LaPorta G, O'Donnell E, Dempsey J, Leonard K. Pilot Trial of Biovance Collagen-Based Wound Covering for Diabetic Ulcers. Advances in Skin & Wound Care. 2009; 22(4):161-166.
75. Mulder G, Tallis A, Marshall V, et al. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): Results of a Phase 1/2 trial. Wound Rep Reg. 2009; 17: 772-779.